Back to Search
DAVID PEEREBOOM, M.D.
M.D.
Specialist
NPI: 1548262512IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
35.057997(OH)
SpecialistPrimary
Specialist
Code: 174400000X
35-05-7997-P(OH)
Education
VIRGINIA COMMONWEALTH UNIVERSITY, SCHOOL OF MEDICINE
Class of 1986
Research & Publications (20)
Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
PMID 19434371·Invest New Drugs·2010
3-trial
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
PMID 18779504·Neuro Oncol·2009
3-trial
Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience.
PMID 19451444·J Clin Oncol·2009
4-observational
Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
PMID 18246536·Cancer·2008
3-trial
Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
PMID 18577560·Neuro Oncol·2008
3-trial
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
PMID 18438609·J Neurooncol·2008
8-other
Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.
PMID 18287342·Neuro Oncol·2008
3-trial
Maculopathy as a complication of blood-brain barrier disruption in patients with central nervous system lymphoma.
PMID 17601426·Am J Ophthalmol·2007
5-case
Chemotherapy delivery issues in central nervous system malignancy: a reality check.
PMID 17538176·J Clin Oncol·2007
6-review
Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting.
PMID 16858513·J Neurooncol·2007
7-preclinical
Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.
PMID 17115898·J Interferon Cytokine Res·2006
3-trial
Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme.
PMID 16086097·Invest New Drugs·2006
3-trial
The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making.
PMID 16619658·J Neurosurg·2006
8-other
Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
PMID 17303909·Med Oncol·2006
3-trial
New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting.
PMID 15701824·Clin Cancer Res·2005
8-other
Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme.
PMID 15936158·Int J Radiat Oncol Biol Phys·2005
8-other
Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).
PMID 15528984·Invest New Drugs·2005
3-trial
Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results.
PMID 12675321·J Neurooncol·2003
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9500 EUCLID AVE, R35
CLEVELAND, OH 44195 - Phone
- (216) 445-6068
Quick Facts
- NPI
- 1548262512
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile